CLO26-102: Progression-Free Survival of Pembrolizumab Monotherapy Versus Combination Therapy With Chemotherapy as First-Line Treatment in Advanced or Metastatic Non-Small-Cell Lung Cancer Without EGFR/ALK Mutations: A Systematic Review and Robust Meta-Analysis